Support for coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform and corporate governance.
2026 · 3rd Quarter (July 1 - Sep 30)
WILLOW LABORATORIES
Filed by WILLOW LABORATORIES.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Sep 30, 2026
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- WILLOW LABORATORIES
- Client
- WILLOW LABORATORIES
- Filing UUID
- 04801a28-213b-4331-83c9-e644c90ab1de
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies
corporate governance and transparency
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.